NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report
related to the Pharmaceutical industry is available in its catalogue.
The Anti-Migraine Market 2007-2022
To order this report:
www.reportlinker.com/p076220/2008/02/06/The-Anti-Migraine-Market-
2007-2022.html
Migraine is a serious neurological disorder characterised by
recurrent headaches, varying in severity and frequency. Accounting for
the loss of over 100 million working days in the US alone, the
economic cost and social impact of migraine is significant.
Furthermore, the people most susceptible to migraine are those within
their most productive years (22-55), causing both personal and
professional disruptions and a significant burden on healthcare
services.
This in-depth management report examines the prospects for
anti-migraine drugs from 2007, right through till 2022. It delivers
sales forecasts for the leading pharmaceutical products, so that you
can analyse your pipeline and market. The market for anti-migraine
drugs is the slowest growing segments in the pain management market
with a CAGR of 0.11% for the period 2006-2012. However this slow
growth will be due to the 2009 patent expiry of the leading product in
the market.
Nevertheless, visiongain predicts that with a high prevalence of
migraine, the success of newer triptans and the launch of new
therapies, the market will expand further beyond 2012, generating
revenues of $5268m in 2022, increasing CAGR for the period 2006-2022
to 2.7%. This detailed report also highlights pipeline developments
and important contemporary issues, especially commercial drivers and
restraints.
The Anti-Migraine Market 2007 examines the market critically
through a comprehensive review of available information. Sources
include industrial databases, commercial news, published reports,
economic research and consultation with experts. Visiongain applies
financial forecasting, qualitative analyses and the assessment of
unmet needs to provide a comprehensive market report with detailed
analysis and informed opinion.
In particular, The Anti-Migraine Market concentrates on the
following essential aspects of the market:
Discussion of the current pharmaceutical market
Forecast of the worldwide pharmaceutical market from 2007-2022
Drivers and restraints facing the anti-migraine market
Opportunities and threats facing the anti-migraine market
Growth of the anti-migraine sector between 2007-2022
Commercial prospects for the market-leading drugs, with sales
forecasts from 2007-2012
The potential of generics manufacturers to penetrate this market
Pipeline developments with blockbuster potential
Currently marketed drugs with blockbuster potential
Discussion of unmet therapeutic needs and relative advantages of
productsWhy you should buy this report:
To receive a comprehensive analysis of the prospects for
anti-migraine drugs from 2007-2012
To discover predicted revenues, growth rates and other key metrics
for leading pharmaceutical treatments from 2007-2012
To determine key activities of leading companies
To discover "hot" pipeline developments and up-and-coming products
To determine the forces that influence the market for
anti-migraine products:
Competitive characteristics of the market
Drivers
Restraints
Strengths, weaknesses, opportunities and threats (SWOT analysis)
To find out where the anti-migraine market is heading - both
technologically and commercially The report provides in-depth market
analysis upon these areas, and extensively identifies both
prescription and OTC drugs. The report also focuses on the
technological issues, including the latest trends, patents, new
products and other influential factors. The study also assesses the
challenges faced by companies in the pain industry, and what exciting
market opportunities exist in this up- and-coming therapeutic area.
Why You Must Buy This Report?
This report features news, insights, the latest developments and
an in depth survey of the pain market with up-to-date analysis as well
as tables, graphs and charts. This report is a vital addition to
gaining an understanding of this market sector and will give your
company 'the edge' on your competitors. You can not afford to be
without this latest report from visiongain.
Unique benefits to you when you order this report
You can access your report whichever country you are in without
using harddrive space
Primary research throughout. You will not find this information
anywhere else
Report stored in your reading room for ever
Full searchable report when you buy the company or corporate
editions
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables
Chapter 1 Executive Summary
Chapter 2 Introduction
2.1 What are Migraines
2.1.1 What Causes Migraine?
2.1.2 Symptom Phases of Migraine
2.1.2.1 Prodrome Phase
2.1.2.2 Auras Phase
2.1.2.3 Attack Phase
2.1.2.4 Postdrome Phase
2.2 What is Headache Pain?
2.2.1 Tension Headaches
2.2.2 Cluster Headaches
2.3 Which Drugs are Approved for Migraine Treatment?
2.3.1 Acute Symptomatic Relief of Migraine Pain
2.3.1.1 What are the Triptans?
2.3.1.1.1 Sumatriptan (Imitrex, Imigran, Imigran Recovery)
2.3.1.1.2 Rizatriptan (Maxalt)
2.3.1.1.3 Zolmitriptan (Zomig)
2.3.1.1.4 Eletriptan (Relpax)
2.3.1.1.5 Naratriptan (Naramig)
2.3.1.1.6 Almotriptan (Axert, Almogran)
2.3.1.1.7 Frovatriptan (Frova)
2.3.1.2 Which Ergots have the FDA Approved for Migraine Treatment?
2.3.1.2.1 Side Effects of Ergots
2.3.1.2.2 Withdrawal of Drug
2.3.1.3 Which Analgesics Have the FDA Approved for Migraine
Treatment?
2.3.1.4 Which Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Have
Been Approved by the FDA?
2.4 Opioids on the Market
2.5 Beta Blockers on the Market
2.6 Anticonvulsants for Migraine (Depakote and Topamax)
2.7 Antidepressants
2.8 Calcium-Channel Blockers
2.9 Other Drug Classes Under Investigation
Chapter 3 The Global Anti-Migraine Market
3.1 The Global Anti-Migraine Market Analysis
3.1.1 GSK's Blockbuster Migraine Drug Imitrex Faces Loss of Sales
3.1.1.1 GSK Waiting Approval for New Potential Anti-Migraine
Blockbuster Drug
3.1.2 AstraZeneca's Zomig - The New Market Leader Perhaps?
3.1.3 Relpax Shows Positive Growth
3.1.4 What Does the Future Hold for Migraine Therapy?
3.1.5 What are the Unmet Needs in the Management of Migraine?
3.1.6 Visiongain Believes That Significant Advances Will Occur in
this Market with Potentially High Revenues for Next-Generation
Products
3.1.7 GSK Currently Leads the Anti-Migraine Market
3.1.8 Imitrex will be Overtaken by Zomig as the Leading
Anti-Migraine Product
3.1.9 The Top Ten Countries in the Anti-Migraine Market
Chapter 4 Forces Affecting the Anti-Migraine Market
4.1 SWOT Analysis of the Anti-Migraine Market
4.1.1 Market Drivers
4.1.2 Market Restraints
4.1.3 Why Growth in the Market is Expected?
4.2 Success of the Triptan Drugs
4.2.1 Niche Markets and the Success of the Triptan
4.2.2 What are the Therapeutic Advantages Offered by the Newer
Triptans?
4.2.3 Will a Single Triptan Reign Supreme?
4.3 Lack of Adequate Reimbursement Limits Potential of
Anti-Migraine Drugs
4.4 Choosing the Right Medication
4.5 Patient Problems with Anti-Migraine drugs
4.6 What are the Costs of Migraine to the US?
4.6.1 Cost of Migraine
4.6.2 How much Does Migraine Cost the US in Terms of Medical,
Missed Workdays and Lost Productivity?
4.7 FDA Reject Endo's Attempt to Expand the Label for Frova
4.8 Complications of the Triptans
Chapter 5 The Prevalence of Migraine
5.1 What is the Global Prevalence of Migraine?
5.1.1 Why Will the Prevalence of Migraine Increase?
5.2 Prevalence of Migraine in the US
5.3 What are the Affects of Migraine on Specific Populations?
5.3.1 Prevalence by Gender
5.3.1.1 Menstrual Migraine
5.3.1.2 Pregnancy and Migraine
5.3.2 Prevalence by Age
5.3.2.1 Migraine in Children
5.3.2.2 Migraine in Later Life
Chapter 6 Pipeline Developments
6.1 Agents in Phase II of Clinical Development
6.1.1 Addex's ADX10059
6.1.2 GSK's 274150, 468816 and 705498
6.2 Agents in Phase III of Clinical Development
6.2.1 Merck's MK0974
6.2.2 GSK's 406381
6.3 Time is Running out for Pozen & GSK After the FDA Request More
Clinical Data on Trexima
6.4 Pozen's MT-100
6.5 Discussion of Current Pipeline Developments
6.6 Summary of Pipeline Products Phase II and Above
Chapter 7 Alternative Therapies
7.1 Acupuncture
7.2 Biofeedback
7.3 Butterbur Root
7.4 Chiropractic
7.5 CoQ10
7.6 Feverfew Leaf
7.7 Ginkgo
7.8 Glucosamine
7.9 Hormones
7.9.1 Melatonin
7.9.2 Estriol
7.10 Magnesium
7.11 NTI Tension Suppression System
7.12 Vitamin B2
Chapter 8 Conclusion
8.1 Migraine is a Serious Condition with High Prevalence
8.2 Migraine Market Analysis
8.2.1 The Anti-Migraine Market Will Suffer From the Patent Expiry
of its Leading Product
8.2.2 How have Anti-Migraine Drugs Succeeded?
8.2.3 How an Increase in Prevalence will affect Sales Growth
8.2.4 Why is a Growth in the Market Expected?
8.2.5 Niche Markets - Menstrual Migraine
8.2.6 Market Drivers
8.2.7 Market Restraints
8.3 Geographical Breakdown of Revenues in the Anti-Migraine Market
8.3.1 Sales of Anti-Migraine Drugs Will Decrease in the US from
2007 to 2012
8.3.2 France Will Have the Second-Highest Sales of Anti-Migraine
Drugs
8.4 There are Promising Developments Currently in Mid to Late
Stage Clinical Testing
8.5 Outlook for the Future of the Anti-Migraine Market
Appendix A: About Visiongain
Appendix B: Visiongain Report Evaluation Form
TABLES
Table 2.1 FDA Approved Triptans for Migraine Treatment
Table 2.2 FDA Approved Ergots for Migraine Treatment
Table 2.3 FDA Approved Analgesics for Migraine Treatment
Table 2.4 FDA Approved NSAIDs for Migraine Treatment
Table 3.1 The World Anti-Migraine Market Forecast ($m), 2007-2022
Table 3.2 Imitrex Forecast ($m), 2007-2012
Table 3.3 Zomig Forecast ($m), 2007-2012
Table 3.4 Relpax Forecast ($m), 2007-2012
Table 3.5 Top 10 Leading Companies in the Anti-Migraine Market,
Revenue and Market Share, 2006
Table 3.6 Top Ten Countries in the Anti-Migraine Market Revenue
($m) Forecast 2007-2012
Table 4.1 SWOT Analysis of the Anti-Migraine Market
Table 4.2 Economic Burden of Migraine in the US
Table 5.1 Lifetime Prevalence of Headaches among Gender
Table 6.1 Summary of Pipeline Products Phase II and Above, 2007
Table 8.1 Geographical Breakdown of Revenues in the Anti-Migraine
Market ($m), 2006-2012
GRAPHS
Graph 1.1 Top Anti-Migraine Products Revenue Forecast ($m),
2007-2012
Graph 3.1 Anti-Migraine World Market Revenue Forecast ($m),
2007-2022
Graph 3.2 Imitrex Revenue Forecast ($m), 2007-2012
Graph 3.3 Zomig Revenue Forecast ($m), 2007-2012
Graph 3.4 Relpax Revenue Forecast ($m), 2007-2012
Graph 3.5 Top 10 Leading Companies in the Anti-Migraine Market
($m), 2006
Graph 8.1 Total Sales of Anti-Migraine Drugs ($m), 2007-2022
Graph 8.2 Sales of the Leading Anti-Migraine Drugs ($m), 2007-2012
CHARTS
Chart 3.1 Leading Companies in the Anti-Migraine Market, Market
Share (%), 2006
Chart 3.2 Top Countries in the Anti-Migraine Market, Market Share
(%), 2006
Chart 3.3 Top Countries in the Anti-Migraine Market, Market Share
(%), 2009
Chart 3.4 Top Countries in the Anti-Migraine Market, Market Share
(%), 2012
More Details
Companies Mentioned in this Report
Abbott Laboratories
Addex
Alexza
Almirall Prodesfarma
Apothecon
AstraZeneca
Bayer
Bedford
Bristol-Myers Squibb
CeNeS
Dr. Reddy's
Elan
Faust Pharmaceuticals
FDA
GD Searle
Geneva Pharmaceuticals
GSK
Harvest Pharms
Houston University
J&J
Lilly
Menarini
Merck & Co
MHRA
Novartis
Odyssey Pharms
Ortho-McNeil
Pfizer
Pharmacia
Pozen
Reckitt Benckiser
Roche
Roxro
Sanofi
UCB
Vernalis
Winston Laboratories
Wyeth
The Anti-Migraine Market 2007-2022
To order this report:
www.reportlinker.com/p076220/2008/02/06/The-Anti-Migraine-Market
-2007-2022.html
(Long URLs in this release may need to be copied/pasted into your
Internet browser's address field. Remove the extra space if one
exists.)
More market research reports?
Go to http://www.reportlinker.com
REPORTLINKER
Copyright Business Wire 2008
